Neurelis to Present Clinical Data on Diazepam Nasal Spray at Epilepsy Meeting
Neurelis, Inc. is set to present a series of clinical data at the American Epilepsy Society Annual Meeting in Atlanta from December 5-9, 2025. The company will showcase eight posters detailing the use of VALTOCO, a diazepam nasal spray, for treating frequent seizures in epilepsy patients aged 2-65 years. The presentations will include findings from the Stellina study, a long-term Phase 1/2a study, and a Phase 3 safety study. These studies focus on the safety, effectiveness, and administration of the nasal spray, particularly in young children. The data highlights the spray's rapid seizure control capabilities and its safety profile, which is consistent across different age groups. Neurelis aims to engage with the epilepsy community to discuss these advancements and improve health outcomes for epilepsy patients.